Case Study: A Biotechnology Company achieves rapid global enrollment and reaches last-patient-in eight months ahead of schedule with IQVIA Biotech

Critical Milestones Achieved Ahead of Schedule in Lung Cancer Study

A Biotechnology Company engaged IQVIA to lead the ex‑North America portion of a global Phase III trial of an investigational ALK inhibitor in non‑small cell lung cancer. The sponsor faced a highly competitive landscape, aggressive regulatory and start‑up timelines, a narrow accrual window to beat competing trials, and the need to integrate site referrals from local MSLs, so they sought an oncology‑focused partner to accelerate site initiation and enrollment.

IQVIA (IQVIA Biotech) delivered rapid start‑up and targeted recruitment support—providing protocol input, country prioritization, targeted feasibility and PI selection, collaboration with the sponsor’s MSLs, site training, and an EDC system live within six weeks. The approach produced measurable impact: an 8% screen‑fail rate, enrollment milestones reached well ahead of plan (25% enrolled two months early, 50% four months early, 75% seven months early) and global last‑patient‑in eight months early; IQVIA also over‑enrolled the ex‑NA target and took on part of the sponsor’s North American accrual.